European Journal of Clinical Pharmacology· 2026Q2
Bir Fransız Üniversite Hastanesinde Bir Farmakovijilans Merkezinin Sağladığı İlaç Bilgi Hizmetinin Klinik Etkisi
Clinical impact of a drug information service provided by a pharmacovigilance centre in a French University Hospital
- 0atıf
- Q2SCImago
- 2026yıl
Kısa özet
Bir Fransız farmakovijilans merkezinin ilaç bilgi hizmeti, karar verilmeden önce danışılan vakaların %86'sında klinik kararları etkiledi (%62 kesin etki, %24 olası etki).
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Ana noktalar
- Bir farmakovijilans merkezinin sağladığı ilaç bilgi hizmeti, karar öncesi sorguların %86'sında klinik kararları etkiledi.
- PVM önerileri, analiz edilen tüm vakaların %87'sinde sonraki klinik yönetimle uyumluydu.
- Hizmet, potansiyel bir güvenlik sinyali dahil 50 farmakovijilans raporu üretti.
- Sorguların çoğu (111/128) advers ilaç reaksiyonları ile ilgiliydi ve hastaneye yatırılmış hastaları (100/128) ilgilendiriyordu.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Özet (abstract)
PURPOSE: Pharmacovigilance Centres (PVCs) provide independent drug information to healthcare professionals in addition to their pharmacovigilance activities. However, their impact on clinical decision-making has been poorly studied. This study assessed the impact of a French PVC on clinical management in a tertiary university hospital (Toulouse University Hospital). METHODS: We conducted a retrospective observational study including all drug-related enquiries submitted to the Toulouse PVC during 2024. Impact was evaluated according to three predefined criteria: whether the enquiry was submitted before or after a clinical management decision had been made, concordance between PVC recommendations and subsequent clinical management, and documentation of the advice in the electronic patient record. Based on these criteria, impact was classified as certain, probable, or uncertain for enquiries submitted before clinical management, and as confirmatory (validating an already implemented decision) or uncertain for enquiries submitted after clinical management had already been initiated. RESULTS: A total of 128 enquiries were analysed. Most concerned adverse drug reactions (111/128), involved hospitalised patients (100/128), and originated from a broad range of clinical departments, mainly geriatrics (14/128), gastroenterology (11/128), neurology (11/128), infectious diseases (10/128) and internal medicine (10/128). Overall, clinical management was concordant with PVC recommendations in 87% of cases. Among the 92 pre-decision enquiries, PVC impact was classified as certain in 62% and probable in 24% of cases. Among the 36 post-decision enquiries, PVC advice was confirmatory in 44% of cases. The enquiries also generated 50 pharmacovigilance reports, including one potential safety signal. CONCLUSION: PVCs support both clinical decision-making and drug safety surveillance.
Yazarların özeti; kaynağından alınmıştır. European Journal of Clinical Pharmacology, 2026 · DOI ↗
Ücretsiz hesapla devam et
Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.
Web'de ücretsiz devam etGoogle ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.
Telefonda:
ToxicologyPharmacology, Toxicology and Pharmaceutics